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Abstract
Background: In patients with multiple sclerosis (MS) the impact of urological symptoms on quality of life and daily
activities is considerable. Yet, a substantial percentage of patients may not be urologically evaluated and thus fail to
be treated concordantly. The 8-item Actionable questionnaire is a validated English screening tool for the detection
of neurogenic bladder overactivity in MS. To enable the use of the 8-item Actionable in The Netherlands and Belgium
we translated the questionnaire into the Dutch language and investigated the test-retest reliability and the concurrent
validity of the Dutch version.
Methods: The process of translating the English Actionable questionnaire into the Dutch language included forward
translations and back-translations. Then, in an online observational study, MS patients completed the Dutch Actionable
at Days 1 and 8, and the Multiple Sclerosis Quality of Life 54-Items (MSQoL-54) and Multiple Sclerosis Impact
Profile (MSIP) questionnaires at Day 1; the Expanded Disability Status Scale (EDSS) score was assessed by phone at Day 1.
For assessment of the test-retest reliability Pearson’s correlation coefficient (r) between the Day 1 and Day 8 Actionable
scores was calculated. For assessment of the concurrent validity r values were calculated between the Day 1 Actionable
score and the EDSS score, the Physical and Mental MSQoL-54 composites, and the MSIP domain and symptom
disability scores.
Results: Study population: N = 141 (106 female, 35 male) (80 relapsing remitting, 48 progressive, 13 unknown),
mean age 47.8 (standard deviation [SD] 10.4) years, mean EDSS score 4.7 (SD 1.8); 137 patients completed the
Day 8 assessment. Pearson’s r between Actionable scores Day 1 and Day 8: 0.85 (P < .0001). Pearson’s r between
Actionable score Day 1 and scores for EDSS 0.41 (P < 0.0001), MSQoL-54 Physical −0.31 (P = 0.0002), MSQoL-54
Mental −0.29 (P = 0.0005), MSIP Excretion and Reproductive Functions 0.44 (P < 0.0001), Muscle and Movement
Functions 0.39 (P < .0001), Basic Movement Activities 0.37 (P < 0.0001), Activities of Daily Living 0.32 (P < 0.0001),
Participation in Life Situations 0.29 (P = 0.0006) and Mental Functions 0.20 (P = 0.0189).
Conclusions: The Dutch version of the Actionable urological screening tool for MS shows a good test-retest
reliability and a good concurrent validity with disabilities and HRQoL.
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Background
Multiple sclerosis (MS) is a chronic inflammatory and
degenerative disease of the central nervous system,
mostly affecting young adults. Up to 80 % of MS pa-
tients will suffer from some degree of bladder dysfunc-
tion in the course of the disease, the most prominent
and disabling symptoms being urinary incontinence,
urge and frequency of urination [1]. The impact of MS-
related urological symptoms on health-related quality
of life (HRQoL) and daily activities is considerable [2].
Moreover, a recent international study showed that in
patients with neurogenic overactive bladder the occur-
rence of incontinence was associated with significantly
higher health care resource utilization, lower HRQoL
and lower productivity [3].
Notwithstanding the clinical and societal conse-
quences of overactive bladder symptoms in MS, there is
evidence that in clinical practice a substantial percent-
age of patients is not being adequately diagnosed and
treated [4]. A large scale survey of the North American
Research Committee On Multiple Sclerosis (NARCOMS)
patient registry identified at least one moderate to severe
urinary symptom in 65 % of the respondents, and showed
that of patients with moderate to severe overactive bladder
symptoms only 43 % were evaluated by urology, that 51 %
were treated with anticholinergic medication, and that
newer treatments were significantly underused (less than
10 % total use) [5]. These findings indicate that despite an
increasing awareness of overactive bladder symptoms and
the need for evaluation and treatment, many MS patients’
symptoms still remain unnoticed and underserved [5, 6].
The 16-items Actionable Bladder Symptom Screening
Tool (ABSST) was developed in response to the grow-
ing need for an accurate way to identify MS patients
with bladder problems [4]. This psychometrically vali-
dated questionnaire identifies MS patients with bladder
symptoms who might benefit from neurogenic detrusor
overactivity-specific treatment [4]. The ABSST asks
questions to uncover whether patients are experiencing
urinary symptoms, to what degree, what the effects of
these symptoms are on daily life, and whether the bladder
issues warrant a visit to a urologist [4]. Soon, a short form
of the 16-items ABSST, the 8-items Actionable ques-
tionnaire was developed, which demonstrated similar
psychometric properties and equally high sensitivity
and specificity as the longer form tool [7].
Health care professionals may consider using the Ac-
tionable questionnaire as a routine standard of care in
their daily practice. It may help to identify those MS pa-
tients who are likely to benefit from an urologic referral
for distressing bladder symptoms. The use of the Action-
able by patients for self-screening purposes in the con-
text of self-management is also conceivable. To enable
the use of the Actionable in The Netherlands and
Belgium, we translated the original English questionnaire
into Dutch and evaluated the test-retest reliability and
concurrent validity of this Dutch version. We demon-
strated the Dutch Actionable to have a good test-retest
reliability (Pearson’s r = 0.85; P < 0.0001) and a good con-
current validity with the Expanded Disability Status
Scale (EDSS) score (r = 0.41; P < 0.0001), and physical
(r = −0.31; P = 0.0002) and mental (r = −0.29; P = 0.0005)
HRQoL.
Methods
Study design and setting
The Dutch Actionable validation study was an obser-
vational, non-interventional, web-based study in The
Netherlands in the period January to May 2015. The
study was investigator-initiated and investigator-sponsored
with financial support from Allergan Pharmaceutical
Ireland Inc.
Inclusion criteria for participation were 1) having
been diagnosed with MS, 2) no relapse in the last
30 days, and 3) willing and able to comply with the re-
quirements of the protocol, i.e. to complete online
questionnaires and to have disability assessed by phone
by an MS nurse (MH). Patients were informed about
the possibility to participate by the urologists and con-
tinence nurses of the urological departments of the
Erasmus Medical Center and the Radboud University
Nijmegen Medical Center, by neurologists and MS
nurses in The Netherlands, by postings on the websites
of the patient organizations Nationaal Multiple Sclerose
Fonds, Multiple Sclerose Vereniging Nederland and
Multiple Sclerose Anders, and the website of the MS4
Research Institute. Patients participating in the web-
based Dutch Multiple Sclerosis Study, a prospective
long-term assessment of HRQoL and disabilities in MS,
were informed via e-mail. The study information and
the consent form were available as download on the
website of the MS4 Research Institute www.ms4ri.nl.
The information given to potential participants con-
cerned the purpose of the study, the eligibility criteria,
the kind of data that were obtained, where the data
were stored, and who the principal investigator (PJJ)
was. No incentives were offered.
After having completed informed consent online and
confirmed their participation by sending their confirm-
ation, the patients received a personal code and logged
on to the website of the MS4 Research Institute, to
choose a username and password. The study was per-
formed using the LimeSurvey software, an open source
online application. There was no testing of the MS4 Re-
search Institute’s platform for this study since it was
already being used in various research projects. The
items of the questionnaire were fixed. The responses
were automatically captured. To protect the personal
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data from unauthorized access various mechanisms were
used to comply with European Union regulations con-
cerning online medical data, including the use of a per-
sonal username and a strong password, separation in the
database of personal information from the answers to
the questions, each screen having a username and pass-
word protection, VPN tunnelling, 256-bits encryption,
and the encryption of the participants’ identities via
unique 15 digits codes. Automated completeness checks
were done before questionnaires could be submitted.
The respondents saw an overview of all questions and
answers before submission and they could change the
answers before submitting. After submission changes
were no longer possible. Only completed questionnaires
were analyzed. The help desk (MH) contacted respon-
dents by phone in case they did not succeed in com-
pleting questionnaires. No methods were used to
adjust for an non-representativeness of the sample.
The study protocol was presented to the ethical com-
mittee Medisch Ethische Toetsingscommissie Brabant
(METC) (nr NW2015-08) and the committee con-
cluded that a review was not indicated, as the study
did not qualify for being tested according to the
Dutch Medical Research Involving Human Subjects
Act of 1999 (www.wetten.overheid.nl/BWBR0009408)
[8]. The study was performed in agreement with the
Declaration of Helsinki (Ethical Principles for Medical
Research Involving Human Subjects version 2013;
64th World Medical Association General Assembly,
Fortaleza, Brazil, October 2013) (www.wma.net) and the
Wet medisch-wetenschappelijk onderzoek met mensen
(WMO) (www.wetten.overheid.nl/BWBR0009408).
The first patient was included on 24th February 2015
and the last patient on 28th April 2015. The closure of
the database was May 7th 2015.
Actionable questionnaire
The 8-item Actionable was developed from the 16-item
ABSST [4, 7] and, as in the ABSST, each item is scored
from 0 (no symptoms or impact) to 3 (extreme symp-
toms or impact). The Actionable score is calculated as
the sum of the item scores on the instrument (total
score) and ranges from 0 (minimum) to 24 (maximum).
Item 9 asks whether the patient would like to receive
help for his or her bladder symptoms (Yes or No). This
item does not contribute to the score.
Health-Related Quality of Life
HRQoL was assessed by the Multiple Sclerosis Quality
of Life 54-Item (MSQoL-54) questionnaire [9]. The
MSQoL-54 is a psychometrically validated, MS-specific,
multi-dimensional inventory of patient-centred health
status, and consists of the Short Form 36-Item (SF-36)
health survey as a generic core measure, supplemented
with 18 questions on items relevant to MS patients in
the areas of health distress, sexual function, satisfaction
with sexual function, overall quality of life, cognitive
function, energy, pain and social function [9]. The
MSQoL-54 contains 52 items distributed into 12 scales,
and two single items. A physical and a mental dimension
underlie the MSQoL-54: the Physical and Mental com-
posites [9]. Scores for the Physical and Mental compos-
ites range from 0 to 100, where higher values indicate
better HRQoL [9].
Disabilities
Disability was measured by use of the Expanded Dis-
ability Status Scale (EDSS) via telephone [10] and by
the Multiple Sclerosis Impact Profile (MSIP) question-
naire online. The classical EDSS is based on a neuro-
logical examination that provides the basis for the
assessment of several functional systems that, according
to predefined algorithms, contribute to the EDSS score
[11]. An EDSS version for use by telephone via a struc-
tured interview has been developed and validated [10].
The MSIP comprises 36 questions assessing disability
(Q1a-Q36a) and disability perception (Q1b-Q36b) in
the domains Muscle and Movement Functions (MMF),
Excretion and Reproductive Functions (ERF), Basic
Movement Activities (BMA), Activities of Daily Living
(ADL), Participation in Life Situations (PLS), Environ-
mental Factors (EF), Mental Functions (MF) and the
symptoms Fatigue, Pain, Speech and Vision [12, 13].
The MSIP yields validated domain scores, ranging from
0 to 12 (ERF, MF), 0 to 15 (BMA), 0 to 16 (MMF), 0 to
20 (EF), 0 to 24 (ADL), and 0 to 26 (PLS), and symp-
toms scores, ranging from 0 to 4. Higher scores indi-
cate a worse condition.
Schedule of assessments
The Actionable questionnaire was completed at baseline
(Day 1) and after one week (Day 8). The MSQoL-54 and
the MSIP were completed at Day 1. The EDSS score was
assessed at Day 1.
Statistics
For assessment of the test-retest reliability Pearson’s co-
efficient was calculated for the correlation between the
Day 1 and Day 8 Actionable scores. For assessment of
the concurrent validity Pearson’s correlation coeffi-
cients were calculated between the Day 1 Actionable
score and the Physical and Mental MSQoL-54 scores,
the EDSS score, and the MSIP domain and symptom
disability scores. P values lower that 0.05 were consid-
ered statistically significant. For the test-retest reliabil-
ity to be qualified as good an r value higher than 0.70
was required.
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Results
Development of Dutch version of actionable
The process of translating the English Actionable question-
naire into the Dutch language included forward translations
and back-translations. The forward translator was a health
professional (PJJ), familiar with the terminology of the area
covered by the questionnaire. He is knowledgeable of the
English-speaking culture but his mother tongue is Dutch.
The translation was conceptual rather than literal, and nat-
ural and acceptable language for the broadest audience was
used. Using the same approach as outlined above, the ques-
tionnaire was then translated back into English by an inde-
pendent translator (TH), whose mother tongue is English
and who has no knowledge of the questionnaire. As in the
initial translation, emphasis in the back-translation was on
conceptual and cultural equivalence and not linguistic
equivalence. This procedure was iterated twice until a
satisfactory version was reached. Figure 1 shows the Dutch
version of the Actionable questionnaire.
Study population
Figure 2 shows the numbers of patients involved in the en-
rolment phase, inclusion phase, concurrent validity analysis,
and test-retest reliability analysis. Of the 141 patients that
were included, 106 were females and 35 males (female-to-
male ratio 3.02). The age (mean, standard deviation [SD])
was 47.7 (10.40) years, the youngest participant being 24 years
and the oldest 73 years. The disease course was relapsing re-
mitting in 80, progressive in 48 and unknown in 13 patients.
The Day 8 assessment was completed by 137 patients.
Actionable, MSQoL-54, EDSS and MSIP values
The mean, SD, minimum and maximum values for the
Actionable score, the Physical and Mental MSQoL-54
Fig. 1 Dutch version of the Actionable questionnaire
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scores, the EDSS score and the MSIP domain and symp-
tom disability scores are presented in Table 1.
Test-retest reliability
Pearson’s r for the correlation between the Actionable
scores at Day 1 and Day 8 was 0.8477 (P < 0.0001).
Concurrent validity
Pearson’s coefficients for the correlations between the
Actionable score at Day 1 and the scores for EDSS,
MSQoL-54 Physical, MSQoL-54 Mental, and the MSIP
domain and symptom disability scores are presented in
Table 2. Statistically significant correlations were found
between the Actionable Day 1 score and the EDSS (0.413,
P < 0.0001), MSQoL-54 Physical (−0.308, P = 0.0002),
MSQoL-54 Mental (−0.292, P = 0.0005), MSIP Muscle
and Movement Functions (0.393, P < .0001), Excretion
and Reproductive Functions (0.437, P < 0.0001), Mental
Functions (0.196, P = 0.0189), Basic Movement Activ-
ities (0.373, P < 0.0001), Activities of Daily Living
(0.322, P < 0.0001), Participation in Life Situations
(0.286, P = 0.0006), Fatigue (0.184, P = 0.032), and
Speech (0.171, P = 0.0426).
Item 9
At Day 1, 57 (40.42 %) patients answered that they
would like to receive help for their bladder symptoms,
whereas 84 (59.57 %) would not like to receive help. At
Day 8, these figures were 61 (44.53 %) and 76 (55.47 %)
respectively, yielding an r value for the correlation be-
tween Day 1 and Day 8 of 0.749 (P < 0.0001). Patients
who would like to receive help (Day 1) had higher Ac-
tionable scores (10.32 [3.84] vs. 6.43 [3.18], P < 0.0001)
(Day 1), lower physical MSQoL-54 scores (49.25 [16.89]
vs. 56.01 [17.33], P = 0.0244), higher EDSS scores
(4.74 [1.69] vs. 4.00 [1.78], P = 0.0131), and higher
MSIP disability scores regarding Muscle and Movement
Functions (6.14 [3.69] vs. 4.53 [3.44], P = 0.0089), Excre-
tion and Reproductive Functions (4.39 [2.37] vs. 2.51
[2.13], P < 0.0001), Mental Functions (3.07 [2.01] vs. 2.36
[1.82], P = 0.0318), Basic Movement Activities (4.54 vs.
2.58 [3.16], P = 0.0013), Activities of Daily Living (8.18
[6.53] vs. 5.89 [5.57], P = 0.0276), Participation in Life
Fig. 2 Numbers of patients involved in the enrolment phase, inclusion phase, concurrent validity analysis, and test-retest reliability analysis
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Situations (5.43 [5.12] vs. 3.53 [3.94], P = 0.0137), and
fatigue (0.53 [0.71] vs. 0.28 [0.48], P = 0.0163).
Discussion
In an online observational study in 141 patients we
assessed the test-retest reliability and the concurrent
validity of a Dutch version of the Actionable question-
naire, an 8-item screening tool for neurogenic bladder
overactivity in MS. The age of our study population (mean
[SD] 47.7 (10.40), minimum 24 and maximum 73 years)
was quite similar to that of the population (N = 151) in
the validation study of the English version (mean [SD]
48.2 (12.11), minimum 22 and maximum of 80 years)
[7]. The Pearson coefficient for the correlation between
the test and retest Actionable scores, that we obtained
with one week interval, was 0.85, which indicates a
good test-retest reliability. The concurrent validity with
respect to MS-related disability was also good, given
the correlation between the Actionable score and the
EDSS (0.41), and correlations between the Actionable
score and the MSIP disability scores for the domains
Muscle and Movement Functions (0.40), Excretion and
Reproductive Functions (0.44), Basic Movement Activ-
ities (0.37), Activities of Daily Living (0.32), and Partici-
pation in Life Situations (0.29). The correlations with
disability relating to Mental Functions, Fatigue and
Speech were less than 0.20. No correlations were found
between the Actionable score and the domain Environ-
mental Factors, and the symptoms Pain and Vision. In
fact, the disabilities showing lower or no correlations,
were those that either regarded specific symptoms (Fatigue,
Speech, Pain, Vision) or non-physical domains (Mental
Functions, Environmental Factors). Thus, overall the find-
ings on the Actionable’s concurrent validity with respect to
MS-related disabilities were as might be expected.
HRQoL is an overall measure of well-being from a pa-
tient’s perspective. Given the potential impact of neuro-
genic bladder symptoms on psychological well-being and
Table 2 Pearson’s coefficients for the correlations between the
Day 1 actionable score and the EDSS, the MSQoL-54 Physical
and Mental, and the MSIP domains and symptom disability scores
Number Pearson’s r P
EDSS 141 0.413 <0.0001
MSQoL-54 Physical 138 −0.308 0.0002
MSQoL-54 Mental 138 −0.292 0.0005
Muscle and Movement Functions 141 0.393 <0.0001
Excretion and Reproductive Functions 141 0.437 <0.0001
Mental Functions 141 0.196 0.0189
Basic Movement Activities 141 0.373 <0.0001
Activities of Daily Living 141 0.322 <0.0001
Participation in Life Situations 141 0.286 0.0006
Environmental Factors 141 0.013 0.8775
Fatigue 136 0.184 0.0320
Pain 141 0.104 0.2197
Speech 141 0.171 0.0426
Vision 131 0.101 0.2130
Table 1 Actionable scores at test (Day 1) and retest (Day 8), and physical and mental MSQoL-54, EDSS, and MSIP domain and
symptom disability scores
Number Mean SD Minimum Maximum
Actionable score Day 1 141 8.00 3.94 0 18
Actionable score Day 8 137 7.61 4.00 0 21
MSQoL-54 Physical 138 53.32 17.42 15.00 96.60
MSQoL-54 Mental 138 64.88 16.92 21.15 95.40
EDSS 141 4.30 1.78 0.00 7.50
Muscle and Movement Functions 141 5.18 3.62 0.00 16.25
Excretion and Reproductive Functions 141 3.27 2.41 0.00 11.00
Mental Functions 141 2.65 1.93 0.00 9.00
Basic Movement Activities 141 3.38 3.60 0.00 15.00
Activities of Daily Living 141 6.82 6.06 0.00 24.00
Participation in Life Situations 141 4.30 4.53 0.00 18.00
Environmental Factors 141 4.78 3.87 0.00 16.00
Fatigue 136 0.38 0.60 0.00 3.00
Pain 141 2.06 0.96 0.00 4.00
Speech 141 0.94 0.85 0.00 4.00
Vision 131 0.72 0.86 0.00 4.00
SD standard deviation
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social functioning, we expected significant correlations
between the Actionable score and the MSQoL-54 com-
posites. Indeed, the associations for the physical and
mental MSQoL-54 composites were −0.31 and −0.29,
respectively, and statistically highly significant, and thus
underlined the concurrent validity of the Dutch Action-
able questionnaire. In the original ABSST and Actionable
validation studies the Overactive Bladder Questionnaire
Short Form (OABq-SF) was used, consisting of a 6-item
symptom-bother scale and a 13-item HRQoL scale. A
Dutch version of the OABq-SF, however, was not available
[14]. Therefore we chose the MSQoL-54, a psychometric-
ally validated scale that is widely used to measure HRQoL
in MS patients [15]. It is of note that the MSQOL-54 is
limited in its coverage of visual function and bladder and
bowel problems [15], which may explain that the correla-
tions between Actionable and MSQoL-54 scores were
somewhat lower than e.g. the correlation between the Ac-
tionable and EDSS.
A limitation of the study is that we did not ask the
clinicians whether they would refer the patient to a
urologist, so we could not compare the Actionable
outcome with the clinical indication. It should also be
noted that the Actionable questionnaire is a screening
tool and not designed for diagnostic purposes [7]. It
aims to select those MS patient who are likely to
benefit from referral to an urologist, in terms of ac-
curate diagnosis and bladder-specific treatment [7].
To achieve this goal the questionnaire may be used
by neurologists, MS nurses, and general physicians in
out-patient settings on a regular basis, both as a paper-
and-pencil test, computer-based or web-based. In view of
the growing possibilities for MS patients to test and screen
themselves online, the Actionable may contribute to pa-
tient self-management as well. E.g. when bladder symp-
toms occur, worsen or change the questionnaire may
constitute an online tool for self-screening. However, the
use should be embedded in the multidisciplinary care pro-
cesses as practiced in the patient’s out-patient clinic, and
according to predetermined rules and agreements. It may
be conceived that a positive self-test is automatically
followed by a set of measures, like testing for a urinary in-
fection and a more comprehensive assessment of bladder
symptoms and function.
Importantly, the optimal frequency of testing has not
been established, neither in general nor in specific set-
tings. A frequent usage could lead to an increased risk
of false-positive outcomes. Moreover, the practicability
of the test in real life practice, its clinical relevance (in
terms of extra urological referrals, more urological
diagnoses and effective bladder-specific treatments) and
cost-effectiveness have not been investigated. The test’s
limited number of items and the established high accur-
acy of the original English version [7] suggest that the
implementation in daily practice may not be major
problem and that the percentage of unnecessary uro-
logical referrals will be limited. Yet, future studies should
address these questions.
Conclusions
In a web-based observational study we validated a
Dutch version of the 8-item Actionable screening ques-
tionnaire for neurogenic bladder overactivity in MS pa-
tients. The Dutch Actionable showed a good test-retest
reliability and a good concurrent validity with disabil-
ities and HRQoL.
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